[go: up one dir, main page]

DK3606519T3 - ASK1-inhibitorforbindelser og anvendelser deraf - Google Patents

ASK1-inhibitorforbindelser og anvendelser deraf Download PDF

Info

Publication number
DK3606519T3
DK3606519T3 DK18780760.7T DK18780760T DK3606519T3 DK 3606519 T3 DK3606519 T3 DK 3606519T3 DK 18780760 T DK18780760 T DK 18780760T DK 3606519 T3 DK3606519 T3 DK 3606519T3
Authority
DK
Denmark
Prior art keywords
inhibitor compounds
ask1 inhibitor
ask1
compounds
inhibitor
Prior art date
Application number
DK18780760.7T
Other languages
English (en)
Inventor
Samuel David Brown
Original Assignee
Seal Rock Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seal Rock Therapeutics Inc filed Critical Seal Rock Therapeutics Inc
Application granted granted Critical
Publication of DK3606519T3 publication Critical patent/DK3606519T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)
DK18780760.7T 2017-04-05 2018-04-04 ASK1-inhibitorforbindelser og anvendelser deraf DK3606519T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762482085P 2017-04-05 2017-04-05
PCT/US2018/026134 WO2018187506A1 (en) 2017-04-05 2018-04-04 Ask1 inhibitor compounds and uses thereof

Publications (1)

Publication Number Publication Date
DK3606519T3 true DK3606519T3 (da) 2024-08-12

Family

ID=63712299

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18780760.7T DK3606519T3 (da) 2017-04-05 2018-04-04 ASK1-inhibitorforbindelser og anvendelser deraf

Country Status (34)

Country Link
US (3) US20210087167A1 (da)
EP (1) EP3606519B1 (da)
JP (1) JP7196093B2 (da)
KR (1) KR102665145B1 (da)
CN (1) CN110730661B (da)
AR (1) AR111407A1 (da)
AU (1) AU2018250217B2 (da)
CA (1) CA3059107A1 (da)
CL (1) CL2019002810A1 (da)
CO (1) CO2019011708A2 (da)
CR (1) CR20190503A (da)
CU (1) CU20190080A7 (da)
DK (1) DK3606519T3 (da)
DO (1) DOP2019000255A (da)
EA (1) EA201992299A1 (da)
EC (1) ECSP19078393A (da)
ES (1) ES2992084T3 (da)
FI (1) FI3606519T3 (da)
HU (1) HUE068103T2 (da)
IL (1) IL269711B (da)
JO (1) JOP20190221A1 (da)
MA (1) MA49047A (da)
MX (1) MX394098B (da)
NI (1) NI201900102A (da)
NZ (1) NZ758345A (da)
PE (1) PE20200009A1 (da)
PH (1) PH12019502288A1 (da)
PL (1) PL3606519T3 (da)
PT (1) PT3606519T (da)
RU (1) RU2019134679A (da)
SG (1) SG11201909155VA (da)
SI (1) SI3606519T1 (da)
TW (1) TWI779022B (da)
WO (1) WO2018187506A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10787435B2 (en) * 2017-01-22 2020-09-29 Fuijan Cosunter Pharmaceutical Co. Ltd. ASK1 inhibitor and preparation method and use thereof
AU2018266911C1 (en) 2017-05-12 2022-10-20 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
EP3735404B1 (en) 2018-01-02 2023-11-29 Seal Rock Therapeutics, Inc. Ask1 inhibitor compounds and uses thereof
CN110407806B (zh) * 2018-04-28 2021-08-17 深圳微芯生物科技股份有限公司 甲酰胺类化合物、其制备方法及其应用
ES3004523T3 (en) 2018-05-02 2025-03-12 Enanta Pharm Inc Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US10654833B2 (en) 2018-06-28 2020-05-19 Hepatikos Therapeutics, Llc ASK1 isoindolin-1-one inhibitors and methods of use thereof
WO2020041417A1 (en) 2018-08-22 2020-02-27 Enanta Pharmaceuticals, Inc. Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2020106707A1 (en) 2018-11-19 2020-05-28 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US11466033B2 (en) 2019-03-25 2022-10-11 Enanta Pharmaceuticals, Inc. Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors
CN112409332B (zh) * 2019-08-23 2023-12-08 广东东阳光药业股份有限公司 三氮唑衍生物及其在药物中的应用
PH12022551585A1 (en) 2019-12-27 2023-11-29 Lupin Ltd Substituted tricyclic compounds
CN115698004A (zh) 2020-05-01 2023-02-03 辉瑞公司 作为hpk1抑制剂的氮杂内酰胺化合物
WO2021224818A1 (en) * 2020-05-08 2021-11-11 Pfizer Inc. Isoindolone compounds as hpk1 inhibitors
WO2022029573A1 (en) * 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AR129959A1 (es) * 2022-07-20 2024-10-16 Seal Rock Therapeutics Inc Método para tratar enfermedades o trastornos orgánicos con inhibidores de ask1
WO2025233319A1 (en) 2024-05-06 2025-11-13 Genfit (1,2,4-triazol-3-yl)-2-pyridyl-1-isoindolinone for use in the treatment of sepsis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
TWI598347B (zh) * 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
PT2531501E (pt) * 2010-02-03 2014-02-17 Takeda Pharmaceutical Inibidores da cinase de regulação do sinal de apoptose 1
WO2012079022A1 (en) * 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
EP2651417B1 (en) 2010-12-16 2016-11-30 Calchan Limited Ask1 inhibiting pyrrolopyrimidine derivatives
JP2017528471A (ja) * 2014-09-24 2017-09-28 ギリアード サイエンシーズ, インコーポレイテッド 肝疾患を処置する方法
WO2017214359A1 (en) * 2016-06-10 2017-12-14 Venenum Biodesign Llc Novel clostridium difficile toxin inhibitors
US10787435B2 (en) 2017-01-22 2020-09-29 Fuijan Cosunter Pharmaceutical Co. Ltd. ASK1 inhibitor and preparation method and use thereof
EA037005B1 (ru) 2017-01-22 2021-01-26 Фуцзянь Косантер Фармасьютикал Ко., Лтд. Производное пиридина в качестве ингибитора ask1 и способ его получения и применения
US11168095B2 (en) 2017-02-07 2021-11-09 Biogen Ma Inc. ASK1 inhibiting agents
WO2018149284A1 (zh) 2017-02-16 2018-08-23 四川科伦博泰生物医药股份有限公司 激酶抑制剂及其制备方法和用途
WO2018151830A1 (en) 2017-02-17 2018-08-23 Fronthera U.S. Pharmaceuticals Llc Pyridinyl based apoptosis signal-regulation kinase inhibitors
WO2018157277A1 (en) 2017-02-28 2018-09-07 Eli Lilly And Company Isoquinolin and naphthydrin compounds
KR20190126322A (ko) 2017-03-03 2019-11-11 장쑤 한서 파마슈티칼 그룹 캄파니 리미티드 아미드 유도체 억제제 및 그의 제조 방법 및 적용
JP2020512976A (ja) 2017-03-27 2020-04-30 ファーマケア,インク. アポトーシスシグナル調節キナーゼ1(ask1)阻害剤化合物
WO2019055540A1 (en) 2017-09-13 2019-03-21 D.E. Shaw Research, Llc COMPOUNDS AS INHIBITORS OF RAS AND THEIR USE
US10654833B2 (en) 2018-06-28 2020-05-19 Hepatikos Therapeutics, Llc ASK1 isoindolin-1-one inhibitors and methods of use thereof

Also Published As

Publication number Publication date
PL3606519T3 (pl) 2024-10-28
PT3606519T (pt) 2024-08-06
AR111407A1 (es) 2019-07-10
CA3059107A1 (en) 2018-10-11
AU2018250217B2 (en) 2022-05-19
US20250304552A1 (en) 2025-10-02
BR112019021021A2 (pt) 2020-05-05
ECSP19078393A (es) 2019-12-27
JP7196093B2 (ja) 2022-12-26
AU2018250217A1 (en) 2019-11-07
JP2020515589A (ja) 2020-05-28
US10150755B2 (en) 2018-12-11
PH12019502288A1 (en) 2020-07-13
NZ758345A (en) 2022-02-25
TW201838983A (zh) 2018-11-01
WO2018187506A1 (en) 2018-10-11
SG11201909155VA (en) 2019-10-30
US20210087167A1 (en) 2021-03-25
SI3606519T1 (sl) 2024-10-30
IL269711A (en) 2019-11-28
US20180291002A1 (en) 2018-10-11
RU2019134679A (ru) 2021-05-05
ES2992084T3 (es) 2024-12-09
CR20190503A (es) 2020-02-28
CN110730661B (zh) 2023-06-13
PE20200009A1 (es) 2020-01-06
KR20190141166A (ko) 2019-12-23
KR102665145B1 (ko) 2024-05-09
HUE068103T2 (hu) 2024-12-28
CL2019002810A1 (es) 2020-03-27
CN110730661A (zh) 2020-01-24
IL269711B (en) 2021-12-01
EP3606519B1 (en) 2024-06-05
DOP2019000255A (es) 2019-12-15
MA49047A (fr) 2020-02-12
TWI779022B (zh) 2022-10-01
MX2019012013A (es) 2019-12-18
MX394098B (es) 2025-03-24
EP3606519A4 (en) 2020-12-02
CO2019011708A2 (es) 2020-01-17
NI201900102A (es) 2020-05-15
CU20190080A7 (es) 2020-10-20
EA201992299A1 (ru) 2020-03-26
JOP20190221A1 (ar) 2019-09-23
EP3606519A1 (en) 2020-02-12
FI3606519T3 (fi) 2024-08-09

Similar Documents

Publication Publication Date Title
DK3606519T3 (da) ASK1-inhibitorforbindelser og anvendelser deraf
IL269196A (en) Novel inhibitors
IL285686B (en) Crystalline solid forms of a bet inhibitor
DK3658557T3 (da) Tyk2-inhibitorer og anvendelser deraf
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
DK3658148T3 (da) Makrocykliske forbindelser og anvendelser deraf
DK3888658T3 (da) Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil
EP3626699A4 (en) SSAO INHIBITOR
DK3389658T3 (da) Glycosidasehæmmere og anvendelser deraf
DK3610005T3 (da) Peptidligase og anvendelse deraf
DK3495023T3 (da) Semifluorerede forbindelser og sammensætninger deraf
DK3571192T3 (da) Jak1-selektive inhibitorer
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
DK3494119T3 (da) Forbindelser og sammensætninger og anvendelser deraf
DK3395801T3 (da) Arylazolforbindelse og skadedyrsbekæmpelsesmiddel
DK3621694T3 (da) Lrrc33-inhibitorer og anvendelse heraf
DK3543240T3 (da) URAT1-inhibitor og anvendelse deraf
DK3474883T3 (da) Komplementinhibitorer og anvendelser deraf
DK3668955T3 (da) Korrosionsinhibitor
DK3672948T3 (da) Pyridinamin-pyridon- og pyrimidinamin-pyridonforbindelser
DK3630744T3 (da) Pyrazol-magl-inhibitorer
MA49006A (fr) Inhibiteurs d'ip6k
DK3606928T3 (da) Makrocyklisk forbindelse og anvendelser deraf
DK3280405T3 (da) Inhibitorer og anvendelser deraf
EP3600301A4 (en) KDM4 INHIBITORS